Moderna Seeks Shareholder Nod for Underwater Option Exchange

TL;DR

**Moderna's option exchange is a necessary, albeit dilutive, move to retain talent and salvage employee morale after a brutal stock price collapse, but it's a band-aid, not a cure for their revenue woes.**

AI Summary

Moderna, Inc. (MRNA) is proposing a one-time stock option exchange program for its non-Executive Committee employees to address significantly 'underwater' stock options, defined as options with an exercise price at or above $80.00 per share, while the stock traded below $24 per share in September 2025. This initiative aims to restore employee motivation and retention, particularly as 90.8% of non-Executive Committee employee options were underwater as of August 27, 2025, when the stock closed at $25.10. The company, which saw revenues decline significantly post-pandemic and anticipates a net loss in 2025, seeks to return to breakeven on a cash cost basis by 2028. The program is designed to be fair-value neutral and anti-dilutive, with new options having an exercise price equal to the fair market value on the new grant date and new vesting terms of at least one year. This exchange is expected to reduce stock option overhang by an estimated 11.1% and fully diluted share count by 0.8%, based on 435,492,735 shares outstanding as of September 30, 2025. The company has already expensed $247 million of the total $354 million in non-cash compensation expense related to these eligible options.

Why It Matters

This option exchange is critical for Moderna's ability to retain key talent amidst a challenging market and declining stock price, which has fallen from approximately $480 in August 2021 to below $24 in September 2025. For investors, it signals a strategic move to realign employee incentives with shareholder interests, potentially reducing future dilution compared to issuing new equity. Employees, particularly those outside the Executive Committee, will see renewed value in their equity compensation, fostering morale and commitment. In a competitive biotech landscape, this program could be a differentiator, allowing Moderna to focus cash reserves on advancing its 30 development candidates and achieving its goal of returning to breakeven by 2028.

Risk Assessment

Risk Level: medium — The risk level is medium because while the option exchange aims to retain employees, it acknowledges significant stock price pressure (below $24 in September 2025 from $480 in August 2021) and anticipated net losses in 2025. The company's ability to return to breakeven by 2028 is a key goal, but its success is not guaranteed, and the program's effectiveness hinges on future stock performance and product approvals.

Analyst Insight

Investors should approve the Option Exchange Proposal as it's a necessary step to stabilize employee morale and retention, crucial for Moderna's long-term strategic execution. However, closely monitor the company's progress on its three strategic priorities, especially driving sales of new products like mRESVIA and mNEXSPIKE, and achieving cost efficiencies to ensure the underlying business fundamentals improve.

Key Numbers

• $25.10 — Closing stock price per share (On August 27, 2025, when the Board authorized the Option Exchange)
• $80.00 — Minimum exercise price for eligible stock options (Threshold for 'underwater' options, more than three times the August 27, 2025 closing price)
• 90.8% — Percentage of outstanding stock options held by non-Executive Committee employees that were underwater (As of August 27, 2025)
• 2028 — Target year for returning to breakeven on a cash cost basis (Strategic goal for Moderna)
• 37.9% — Percentage of eligible stock options with exercise price >= $80.00 (Out of 14,886,068 shares held by non-Executive Committee employees as of September 30, 2025)
• $124.24 — Weighted average exercise price of eligible stock options (As of September 30, 2025)
• $354 million — Total non-cash compensation expense related to eligible underwater stock options (Required to be recognized under accounting rules)
• $247 million — Non-cash compensation expense already expensed (As of September 30, 2025, related to eligible underwater stock options)
• 11.1% — Estimated net reduction in stock option overhang (If all eligible stock options are exchanged)
• 0.8% — Estimated net reduction in fully diluted share count (Based on 435,492,735 shares outstanding as of September 30, 2025)

Key Players & Entities

• Moderna, Inc. (company) — Registrant seeking shareholder approval
• Stéphane Bancel (person) — Chief Executive Officer and Director
• The Nasdaq Global Select Market (regulator) — Stock exchange where Moderna's common stock trades
• Pay Governance (company) — Advisor to the Compensation and Talent Committee
• U.S. Food and Drug Administration (regulator) — Approved mRESVIA and mNEXSPIKE
• Spikevax (company) — Moderna's original COVID vaccine
• mRESVIA (company) — Moderna's mRNA RSV vaccine
• mNEXSPIKE (company) — Moderna's new COVID-19 vaccine
• Executive Committee (person) — Group of employees excluded from the option exchange program
• Board of Directors (person) — Authorized the Option Exchange subject to shareholder approval

FAQ

Risk Factors

• Stock Price Volatility and Underwater Stock Options [high — market]: Moderna faces significant risk due to its stock price trading well below the exercise price of many employee stock options. As of August 27, 2025, 90.8% of non-Executive Committee employee options were underwater, with exercise prices at or above $80.00 while the stock traded at $25.10. This situation severely impacts employee motivation and retention, necessitating a one-time option exchange program.
• Revenue Decline and Path to Profitability [high — financial]: The company experienced significant revenue declines post-pandemic and anticipates a net loss in 2025. The strategic goal is to return to breakeven on a cash cost basis by 2028, indicating ongoing financial challenges and the need for careful cost management and revenue generation.
• Employee Retention and Motivation [medium — operational]: A large percentage of employee stock options being 'underwater' poses a substantial risk to employee morale, motivation, and retention. The proposed option exchange program aims to mitigate this by restoring some equity value, but its success in fully addressing these issues is not guaranteed.

Industry Context

Moderna operates in the biotechnology sector, specifically focusing on messenger RNA (mRNA) medicine. The company has been a pioneer in developing mRNA-based therapies and vaccines at an unprecedented speed. The industry is characterized by rapid innovation, high R&D costs, and significant regulatory hurdles.

Regulatory Implications

The proposed stock option exchange program must comply with accounting standards for stock-based compensation and securities regulations regarding disclosures and shareholder approvals. The fair-value neutral design aims to manage the accounting impact, but any miscalculation or misrepresentation could lead to regulatory scrutiny.

What Investors Should Do

1. Review the terms and conditions of the proposed Option Exchange Program.
2. Evaluate the company's financial outlook and path to breakeven.
3. Assess the anti-dilutive nature of the proposed exchange.

Key Dates

• 2025-08-27: Board authorized the Option Exchange program — Marks the formal decision to address the issue of underwater stock options for non-Executive Committee employees.
• 2025-09-30: Reporting date for share count and option data — Provides the baseline figures for calculating the impact of the proposed option exchange on dilution and overhang.

Glossary

Underwater stock options

Stock options where the current market price of the underlying stock is lower than the exercise price of the option. (This is the core problem the proposed exchange program aims to solve, as 90.8% of eligible employee options were underwater.)

Option Exchange Program

A program where employees can surrender their existing, out-of-the-money stock options in exchange for new stock options with a lower exercise price and potentially new vesting terms. (This is the specific proposal being put forth for shareholder approval to address employee compensation and retention.)

Fair-value neutral

An accounting principle indicating that the total fair value of the stock options granted does not change as a result of the exchange. (This is a key design feature of the proposed program, intended to avoid additional compensation expense beyond what has already been recognized.)

Anti-dilutive

A program designed to minimize or prevent an increase in the total number of outstanding shares, thereby protecting the value of existing shares. (The program is designed to be anti-dilutive, with an estimated reduction in the fully diluted share count by 0.8%.)

Stock option overhang

The number of outstanding stock options that are not yet vested or are 'underwater', relative to the total number of shares outstanding. (The exchange is expected to reduce stock option overhang by an estimated 11.1%, indicating a significant improvement in the option landscape.)

Year-Over-Year Comparison

This filing focuses on a specific proposal for a one-time stock option exchange program, a situation not detailed in previous filings. The context provided highlights a significant shift from previous periods, with revenues declining post-pandemic and a substantial portion of employee stock options being 'underwater' ($80.00 exercise price vs. $25.10 stock price). This contrasts with periods where the company likely experienced strong revenue growth and stock performance, necessitating a strategic adjustment to retain talent.

Key Financial Figures

• $80.00 — ar and have exercise prices at or above $80.00 (above our 52-week stock price high) to
• $480 — reached historic highs of approximately $480 per share in August 2021 as investors r
• $24 — .S., with our stock price trading below $24 per share as recently as September 2025
• $25.10 — on The Nasdaq Global Select Market was $25.10 per share, resulting in 90.8% of our ou
• $74.35 — th a weighted average exercise price of $74.35 per share. Of these stock options, 37.9
• $124.24 — ve a weighted average exercise price of $124.24 per share. The $80.00 per share thresho
• $10.90 — s, with a range in exercise prices from $10.90 per share to $416.70 per share. As a re
• $416.70 — xercise prices from $10.90 per share to $416.70 per share. As a result, we have develop
• $99.99 — tions to New Stock Options) $80.00 to $99.99 2,500,047 8.33 2.0 to 1 $100.00 to $
• $100.00 — 00 to $99.99 2,500,047 8.33 2.0 to 1 $100.00 to $149.99 2,205,365 7.21 3.0 to 1 $
• $149.99 — 9 2,500,047 8.33 2.0 to 1 $100.00 to $149.99 2,205,365 7.21 3.0 to 1 $150.00 to $
• $150.00 — 0 to $149.99 2,205,365 7.21 3.0 to 1 $150.00 to $199.99 758,060 6.54 4.0 to 1 $20
• $199.99 — 9 2,205,365 7.21 3.0 to 1 $150.00 to $199.99 758,060 6.54 4.0 to 1 $200.00 to $29
• $200.00 — .00 to $199.99 758,060 6.54 4.0 to 1 $200.00 to $299.99 85,959 5.93 4.5 to 1 $300
• $299.99 — .99 758,060 6.54 4.0 to 1 $200.00 to $299.99 85,959 5.93 4.5 to 1 $300.00 and abo

Filing Documents

• mrna-optionexchangedefinit.htm (DEF 14A) — 265KB
• a02_pro013195xiconxhowtovo.jpg (GRAPHIC) — 36KB
• a02_pro013195xiconxhowtovoa.jpg (GRAPHIC) — 38KB
• a02_pro013195xiconxhowtovob.jpg (GRAPHIC) — 36KB
• image_0.jpg (GRAPHIC) — 11KB
• image_1.jpg (GRAPHIC) — 5KB
• image_5.jpg (GRAPHIC) — 1KB
• image_7.jpg (GRAPHIC) — 1KB
• image_9.jpg (GRAPHIC) — 87KB
• page1defproxycarda.jpg (GRAPHIC) — 158KB
• page2defproxycarda.jpg (GRAPHIC) — 174KB
• 0001682852-25-000062.txt ( ) — 988KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 16 Information About the Special Meeting of Shareholders 18 2 Moderna Special Meeting Proxy Statement PROPOSAL 1 Approval of a One-Time Stock Option Exchange Program for Non-Executive Committee Employees Introduction We are seeking shareholder approval of an option exchange program (the Option Exchange), that would allow eligible employees who are not members of our Executive Committee (which includes all of our executive officers) or members of our Board of Directors to exchange significantly out-of-the-money or "underwater" stock options, meaning outstanding stock options that have an exercise price that is significantly greater than the market price for our stock, for the issuance of new stock options that will be exercisable for fewer shares of our common stock, with an exercise price equal to the fair market value of our common stock on the new grant date and with new vesting terms. The new stock options would continue to have the same expiration date. We would like to offer this program to our non-Executive Committee employees because we believe that it will provide a much less dilutive and more cost-effective retention and incentive tool than issuing additional equity or paying more cash compensation in order to continue to retain and motivate these employees. We designed the Option Exchange with the goals of restoring equity value for our non-Executive Committee employees, increasing employee retention and motivation in a competitive labor market, and better aligning our employee and shareholder interests for long-term growth. The proposed Option Exchange has the following key features Executive Committee members, consultants, advisors and members of our Board of Directors will not be eligible to participate options must have been outstanding for at least one year and have exercise prices at or above $80.00 (above our 52-week stock price high) to be eligible only stock options a

View Full Filing

View this DEF 14A filing on SEC EDGAR